Crescent Biopharma (NASDAQ: CBIO) revenue
Crescent Biopharma reported revenue of $10.8m for fiscal 2025; in fiscal 2023 it was $0.0m. Since fiscal 2016 its revenue has grown by 58,516.2%, an average growth of 103.0% a year.
Fiscal 2025 is the highest of the 6 fiscal years on record for Crescent Biopharma. The biggest drop was in fiscal 2022, −93.5%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $10.8m | — | −$152.6m | −1,407.5% |
| 2023 | $0.0m | −86.7% | −$39.3m | −392,752.9% |
| 2022 | $0.1m | −93.5% | −$47.4m | −63,204.4% |
| 2021 | $1.2m | −88.6% | −$63.4m | −5,470.7% |
| 2020 | $10.2m | — | −$51.5m | −506.8% |
| 2016 | $0.0m | — | −$31.9m | −172,505.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Crescent Biopharma revenue compared with its sector
By revenue for its latest fiscal year, Crescent Biopharma ranks 366th of the 422 US health care companies with a page on Celsmar.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 364th | Prelude Therapeutics | $12.1m | 73.4% |
| 365th | Caribou Biosciences | $11.2m | 11.7% |
| 366th | Crescent Biopharma | $10.8m | — |
| 367th | Janux Therapeutics | $10.0m | −5.6% |
| 368th | Zenas BioPharma | $10.0m | 100.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Crescent Biopharma
- How much revenue did Crescent Biopharma make in fiscal 2025?
- Crescent Biopharma reported revenue of $10.8m for fiscal 2025, compared with $0.0m in fiscal 2023.
- How much has the revenue of Crescent Biopharma grown?
- Between fiscal 2016 and fiscal 2025 it went from $0.0m to $10.8m: 58,516.2% more, an average growth of 103.0% a year.
- What was the best year for revenue at Crescent Biopharma?
- Of its last 6 fiscal years, fiscal 2025, with $10.8m.
- Where does Crescent Biopharma rank in its sector by revenue?
- It ranks 366th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Crescent Biopharma come from?
- From the annual report (Form 10-K) that Crescent Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Crescent Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2023 · 2022 · 2021 · 2020 · 2016. More on Crescent Biopharma: the Crescent Biopharma page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.